WHO Pharmaceuticals Newsletter 2004, No. 01
(2004; 17 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentANTIEPILEPTICS - ADR update from Australia
Afficher le documentBOTULINUM TOXIN TYPE A - Place in therapy not clearly defined
Afficher le documentCELECOXIB/ROFECOXIB - Acute temporary visual impairment
Afficher le documentDACLIZUMAB - Increased mortality in cardiac transplant patients
Afficher le documentFLUTICASONE - Update on adrenal insufficiency reports
Afficher le documentINTERFERON BETA - Safety information about risk of liver injury
Afficher le documentMETHADONE - Risk of QT prolongation
Afficher le documentMETHOTREXATE - Update on pulmonary effects
Afficher le documentMIRTAZAPINE - ADR update from Australia
Afficher le documentMORPHINE - Accidental overdose of concentrated oral solutions
Afficher le documentNONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) - Postpartum administration may cause hypertension
Afficher le documentPERGOLIDE - Danger of falling asleep during daily activities
Afficher le documentPYRAZINAMIDE & RIFAMPICIN - Serious liver injury with combined use in latent tuberculosis
Afficher le documentSIBUTRAMINE - ADR update
Afficher le documentTOPIRAMATE - Warning about metabolic acidosis
Afficher le documentWARFARIN - Interaction with cranberry juice
Ouvrir ce répertoire et afficher son contenuDRUGS OF CURRENT INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE
 

METHADONE - Risk of QT prolongation

Switzerland. On 15 January the Swiss regulatory agency, Swissmedic, issued a warning message regarding the risk of QT prolongation, including Torsade de pointes, after high-dose methadone substitution therapy for heroin addicts or used as an analgesic. The Swissmedic has 25 reports covering a total of 42 adverse reactions including suspected heart-rate disturbances associated with methadone, constituting 15.4% of all reports received on the drug. Reference is made to several published studies on this topic. The message lists a number of risk factors that need to be considered when methadone is prescribed. Further information about this advice may be requested from the Swissmedic information office at: info@swissmedic.ch

Reference:

1. Electronic mail received from the WHO Collaborating Centre, Sweden, via Vigimed, 16 January 2003.

2. Communication from Swissmedic, 21 January 2003.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013